Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...

Immune checkpoint inhibitors (ICPis) have revolutionized the therapeutic landscape of lung cancer with unprecedented survival results in most of the ...

Recent health updates include the U.S. participating in WHO meetings, UK approval of a Moderna vaccine, a Texas measles ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...